Skip to main content
. 2018 Oct 30;144(4):841–847. doi: 10.1002/ijc.31809

Figure 2.

Figure 2

 Mutation status‐dependent poor‐prognostic impact of KRAS splicing. Among patients with Stage I–III MSS CRC, a low KRAS‐4A splicing index (below median) was associated with poor survival specifically in the KRAS wild‐type subgroup (5‐year overall survival: 85% vs. 68%), but not in patients harboring tumors with KRAS mutations.